Friday, Jan 15, 2021
By Narayana Krishna
HYDERABAD – Pfizer Inc and associate companies have sued Aurobindo Pharmaceuticals Ltd in a US court for patent infringement of its arthritis drug Xeljanz.
The patent violation petition was filed on Jan 11 at the US District Court for the District court of Delaware, according to a court document reviewed by Cogencis.
In November, Aurobindo Pharma had informed Pfizer about filing an Abbreviated New Drug Application with the US Food & Drug
Administration, seeking approval to make a generic of Xeljanz, Tofacitinib, in 5- and 10-mg dosages.
Xeljanz is used to treat rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.
Pfizer sought the injunction order to prevent Aurobindo Pharma and its US arm from making and selling the drug in the US before its patent expiry.
Pfizer’s patents on the said drug set to expire in 2023 and 2025.
At 0958 IST, shares of Aurobindo Pharma were 2.2% lower at 937.70 rupees on National Stock Exchange. End
IST, or Indian Standard Time, is five-and-a-half hours ahead of GMT
Edited by Subham Mitra
Cogencis Tel +91 (11) 4220-1000
Send comments to feedback@cogencis.com
.
Informist, Tuesday, Jun 6, 2023 –Tata Consumer: Consolidating JV ownerships in S Africa, Bangladesh–Tata Consumer MD, CEO: India FY23 foods ops revenue up 26%–Tata Consumer MD, CEO: India beverage ops revenue rose 1% in FY23–Tata Consumer: Sales ratio improved to 3.4% in FY23–Tata Consumer: Expect to complete Tata Coffee merger this year–Tata Consumer: FY23 margin hit […]
Informist, Tuesday, Jun 6, 2023 –Sources: National infra financing bk plans up to 100-bln-rupee bonds–National infra financing bk may seek bids for bonds this mo By Subhana Shaikh MUMBAI – National Bank for Financing Infrastructure and Development, also known as NaBFID, plans to tap the debt market with its maiden bond issue, worth up to 100 bln rupees, this month, sources aware of the […]
Informist, Tuesday, Jun 6, 2023 By Vivek Kumar MUMBAI – Earnings expectations of domestic information technology companies took a hit today after the US-based software engineering company EPAM Systems lowered its revenue growth guidance, citing caution among clients with respect to technology spending. "In the weeks since our Q1 (Jan-Mar) earnings call, we have seen our clients become even […]
Follow Informist
